Parallel Advisors LLC Raises Stock Holdings in Danaher Corporation $DHR

Key Points

• Parallel Advisors LLC increased its stock holdings in Danaher Corporation by 9.9% during the second quarter, owning a total of 19,141 shares valued at approximately $3.78 million.
• Danaher reported a quarterly earnings per share of $1.80, exceeding analyst estimates, with a year-over-year revenue growth of 3.4% to $5.94 billion.
• The company recently declared a quarterly dividend of $0.32 per share, translating to a 0.7% yield, with an upcoming ex-dividend date on September 26th.

Parallel Advisors LLC boosted its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 9.9% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 19,141 shares of the conglomerate's stock after acquiring an additional 1,732 shares during the quarter. Parallel Advisors LLC's holdings in Danaher were worth $3,781,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Heck Capital Advisors LLC bought a new position in shares of Danaher in the fourth quarter worth about $27,000. GHP Investment Advisors Inc. boosted its position in Danaher by 396.0% in the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after buying an additional 99 shares during the period. Sierra Ocean LLC grew its stake in Danaher by 116.9% in the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock worth $29,000 after acquiring an additional 76 shares in the last quarter. Smallwood Wealth Investment Management LLC purchased a new position in shares of Danaher during the first quarter worth approximately $31,000. Finally, Dunhill Financial LLC raised its stake in shares of Danaher by 68.4% during the first quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock valued at $34,000 after acquiring an additional 67 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Danaher Trading Down 1.0%

Shares of NYSE:DHR opened at $188.24 on Tuesday. The business has a 50-day moving average price of $200.98 and a 200-day moving average price of $198.64. The stock has a market cap of $134.79 billion, a price-to-earnings ratio of 40.05, a PEG ratio of 2.65 and a beta of 0.75. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.90. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The business had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. During the same quarter last year, the business posted $1.72 EPS. The company's revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, September 26th. Danaher's dividend payout ratio is presently 27.23%.

Insider Activity at Danaher

In related news, Director Teri List sold 2,778 shares of Danaher stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the transaction, the director owned 20,751 shares in the company, valued at $4,379,706.06. The trade was a 11.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 11.20% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms have commented on DHR. Scotiabank upgraded Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective on the stock in a report on Friday, July 11th. Barclays restated an "overweight" rating and issued a $225.00 price objective (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Evercore ISI dropped their target price on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Finally, Wells Fargo & Company dropped their price objective on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 23rd. Seventeen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $246.35.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.